Evidence on the associations and safety of COVID-19 vaccination and post COVID-19 condition: an updated living systematic review.

IF 2.5 4区医学 Q3 INFECTIOUS DISEASES

Epidemiology and Infection Pub Date : 2025-03-31 DOI:10.1017/S0950268825000378

Melanie Sterian, Thivya Naganathan, Tricia Corrin, Lisa Waddell

{"title":"Evidence on the associations and safety of COVID-19 vaccination and post COVID-19 condition: an updated living systematic review.","authors":"Melanie Sterian, Thivya Naganathan, Tricia Corrin, Lisa Waddell","doi":"10.1017/S0950268825000378","DOIUrl":null,"url":null,"abstract":"Post COVID-19 condition (PCC) refers to persistent symptoms occurring ≥12 weeks after COVID-19. This living systematic review (SR) assessed the impact of vaccination on PCC and vaccine safety among those with PCC, and was previously published with data up to December 2022. Searches were updated to 31 January 2024 and standard SR methodology was followed. Seventy-eight observational studies were included (47 new). There is moderate confidence that two doses pre-infection reduces the odds of PCC (pooled OR (pOR) 0.69, 95% CI 0.64-0.74, I2 = 35.16%). There is low confidence for remaining outcomes of one dose and three or more doses. A booster dose may further reduce the odds of PCC compared to only a primary series (pOR 0.85, 95% CI 0.74-0.98, I2 = 16.85%). Among children ≤18 years old, vaccination may not reduce the odds (pOR 0.79, 95% CI 0.56-1.11, I2 = 37.2%) of PCC. One study suggests that vaccination within 12 weeks post-infection may reduce the odds of PCC. For those with PCC, vaccination appears safe (four studies) and may reduce the odds of PCC persistence (pOR 0.73, 95% CI 0.57-0.92, I2 = 15.5%).","PeriodicalId":11721,"journal":{"name":"Epidemiology and Infection","volume":" ","pages":"e62"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038765/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epidemiology and Infection","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/S0950268825000378","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Post COVID-19 condition (PCC) refers to persistent symptoms occurring ≥12 weeks after COVID-19. This living systematic review (SR) assessed the impact of vaccination on PCC and vaccine safety among those with PCC, and was previously published with data up to December 2022. Searches were updated to 31 January 2024 and standard SR methodology was followed. Seventy-eight observational studies were included (47 new). There is moderate confidence that two doses pre-infection reduces the odds of PCC (pooled OR (pOR) 0.69, 95% CI 0.64-0.74, I² = 35.16%). There is low confidence for remaining outcomes of one dose and three or more doses. A booster dose may further reduce the odds of PCC compared to only a primary series (pOR 0.85, 95% CI 0.74-0.98, I² = 16.85%). Among children ≤18 years old, vaccination may not reduce the odds (pOR 0.79, 95% CI 0.56-1.11, I² = 37.2%) of PCC. One study suggests that vaccination within 12 weeks post-infection may reduce the odds of PCC. For those with PCC, vaccination appears safe (four studies) and may reduce the odds of PCC persistence (pOR 0.73, 95% CI 0.57-0.92, I² = 15.5%).

查看原文本刊更多论文

COVID-19疫苗接种与COVID-19后病情的相关性和安全性的证据：最新的活系统综述

COVID-19后症状（PCC）是指在COVID-19后出现≥12周的持续症状。这项实时系统评价（SR）评估了疫苗接种对PCC的影响以及PCC患者的疫苗安全性，之前发表的数据截至2022年12月。搜索更新至2024年1月31日，并遵循标准SR方法。纳入了78项观察性研究（47项新研究）。有中等可信度，两剂感染前可降低PCC的发生率（合并OR (pOR) 0.69, 95% CI 0.64-0.74, I2 = 35.16%）。一剂和三剂或更多剂量的剩余结果的置信度很低。与初级系列相比，加强剂量可进一步降低PCC的发生率（pOR 0.85, 95% CI 0.74-0.98, I2 = 16.85%）。在≤18岁的儿童中，接种疫苗可能不会降低PCC的发生率（pOR 0.79, 95% CI 0.56-1.11, I2 = 37.2%）。一项研究表明，在感染后12周内接种疫苗可能会降低PCC的发病率。对于那些患有PCC的人，接种疫苗似乎是安全的（四项研究），并可能降低PCC持续存在的几率（pOR 0.73, 95% CI 0.57-0.92, I2 = 15.5%）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Epidemiology and Infection 医学-传染病学

CiteScore

4.10

自引率

2.40%

发文量

366

审稿时长

3-6 weeks

期刊介绍： Epidemiology & Infection publishes original reports and reviews on all aspects of infection in humans and animals. Particular emphasis is given to the epidemiology, prevention and control of infectious diseases. The scope covers the zoonoses, outbreaks, food hygiene, vaccine studies, statistics and the clinical, social and public-health aspects of infectious disease, as well as some tropical infections. It has become the key international periodical in which to find the latest reports on recently discovered infections and new technology. For those concerned with policy and planning for the control of infections, the papers on mathematical modelling of epidemics caused by historical, current and emergent infections are of particular value.